Compare New York Times Co (NYT) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
New York Times Co vs Viatris Inc — how do they compare? New York Times Co trades at $75.56 (market cap $12.29B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| NYT | VTRS | |
|---|---|---|
Market Cap | $12.29B | $19.79B |
Sector | Media | Health |
52-Week High | $85.86 | $17.39 |
52-Week Low | $51.43 | $8.74 |
Enterprise Value | $11.68B | $32.00B |
Dividend Yield | 1.21% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The New York Times Company (NYSE: NYT) trades at $74.69, down 1.63% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $2.82 billion in 2025, with net income margin expanding to 12.17%. The stock is supported by strong cash flow from operations of $584 million and a consensus analyst price target of $78.00. Recent news includes the company's motion to quash subpoenas related to reporting on Air Force One, highlighting ongoing legal and press freedom challenges.
Outlook remains positive with consistent earnings growth and a defensive profile amid geopolitical tensions, but risks include regulatory pressures and competitive threats to digital subscriptions. The stock offers a dividend yield with the next payment scheduled for July 23, 2026. Institutional sentiment is mixed with a majority hold rating, suggesting cautious optimism for near-term appreciation toward the price target.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About New York Times Co
New York Times Co is an American media company known for publishing its flagship newspaper, The New York Times. The company also operates the International New York Times newspaper, as well as digital properties such as nytimes and various smartphone applications. Circulation of The New York Times is the source of revenue for the company, followed by print and digital advertising and its paid digital-only subscription to The New York Times. The company has a daily print circulation of over 500,000 and 1,000,000 on Sundays. The source of growth for The New York Times is its digital subscription service, which has over 1,000,000 paid users.
Read more on NYT →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
